Atypical cystic fibrosis: from the genetic causes to current and future treatments by Quinn, Ryan Kelley
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Atypical cystic fibrosis: from the
genetic causes to current and
future treatments
https://hdl.handle.net/2144/16830
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
ATYPICAL CYSTIC FIBROSIS: FROM THE GENETIC CAUSES TO 
CURRENT AND FUTURE TREATMENTS 
 
 
 
 
by 
 
 
 
 
RYAN QUINN 
 
B.S., University of California, Santa Barbara, 2013 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
 RYAN QUINN 
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 Matthew D. Layne, Ph.D 
 Associate Professor of Biochemistry 
 
 
Second Reader   
 Karen Symes, Ph.D 
 Associate Professor of Biochemistry 
   
  
 
   
  
 
 
	  	   iv 
 
ACKNOWLEDGMENTS 
 
I would like to sincerely thank my thesis readers: Dr. Matthew Layne (first 
reader) and Dr. Karen Symes (second reader). Dr. Layne not only served as the first 
reader of my thesis, but also served as my advisor throughout the MAMS program. Dr. 
Layne spent countless hours meeting with me and preparing me for medical school 
interviews – going far beyond the typical job description of a graduate student advisor, 
and mentor. I can’t thank Dr. Layne enough for his continuous support throughout my 
time at Boston University. 
Second, I would like to thank my parents for their support of my goal to pursue a 
career in medicine, and their unwavering confidence in me. This program represented a 
significant investment in my future, and I am grateful for their help. 
Third, I would like to acknowledge my many dedicated peers that I met through 
the program. I enjoyed the collaboration and the journey together in pursuit of our shared 
dream to make a difference to others through medicine. 
  
	  	   v 
ATYPICAL PRESENTATION OF CYSTIC FIBROSIS: FROM THE GENETIC 
CAUSES TO CURRENT AND FUTURE TREATMENTS 
RYAN QUINN 
ABSTRACT 
 Cystic Fibrosis (CF) is a life threatening autosomal recessive disorder caused by a 
mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, 
leading to irregular secretions and inflammation in tubular organs. Disease manifestations 
of CF are heterogeneous in severity and can be present in the sinopulmonary, hepatic, 
gastrointestinal, and genitourinary tract. Since the 1960’s, physicians and scientists have 
described a less severe form of CF known as atypical CF, usually seen in adults. Patients 
with atypical CF tend to have one severe CF mutation on one chromosome, and one less 
common, mild CF mutation on their other chromosome; or have one severe mutation on 
one chromosome and an abnormal number of trinucleotide repeats in the CFTR gene on 
their other chromosome. Today, of the approximately 1000 patients diagnosed with CF 
per year in the United States, roughly 10% are diagnosed with the atypical presentation of 
the disease as adults. Patients suffering from atypical CF typically have only one organ 
system that is dysfunctional, and their clinical symptoms may be less severe than those of 
a classical case where there are two severe CF mutations. Common symptoms include 
idiopathic bronchiectasis, chronic sinusitis, congenital bilateral absence of the vas 
deferens (CBAVD), and idiopathic pancreatitis. Unlike patients suffering from the 
classical presentation of the disease, most are pancreatic sufficient – however the 
possibility of pancreatic insufficiency still exists. Patients with atypical CF represent a 
	  	   vi 
diagnostic challenge for physicians due to the mild, slowly progressing array of clinical 
symptoms, the general lack of knowledge about atypical CF, and the general association 
of CF as a childhood disease. Increasing physician awareness of the adult population with 
CF is a paramount in improving the diagnosis, care and treatment of patients with 
atypical CF. Missed diagnoses can result in hospital admissions and morbidity that may 
have been avoidable. The goal of this thesis is to describe the causes of CF, the common 
symptoms seen in both CF and atypical CF, the proper diagnosis of atypical CF, and to 
identify the therapies, both current and in development, used to treat atypical CF. 
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INTRODUCTION 
Cystic fibrosis (CF) is a life threatening autosomal recessive disorder, caused by a 
defect in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene [1]. 
The CFTR gene codes for a cAMP (cyclic adenosine monophosphate) dependent chloride 
channel at the apical epithelial cell surface, which is important for maintaining ion 
gradients and the subsequent flow of water across membranes in tubular structures [2, 3, 
4]. Dysfunction in the CFTR chloride channel can lead to impairment of pulmonary, 
pancreatic, hepatic, intestinal, and genitourinary system function due to abnormal viscous 
mucous secretions and fluid flow. These viscous secretions lead to chronic inflammation, 
tissue damage and the impairment of proper organ function [5]. Clinically, CF is a 
heterogeneous disorder: patients present with a multitude of symptoms in different organ 
systems with varying degrees of severity. Approximately 90% of patients are diagnosed 
in infancy due to pulmonary dysfunction or pancreatic insufficiency, however, the 
diagnosis of CF can also occur in adulthood [6, 7]. In fact, one case report identified a 70-
year-old patient, who had been diagnosed with atypical CF [8]. CF has been found in all 
racial groups, and is the most frequent life limiting genetic disease in the Caucasian 
population [3]. More than 30,000 people in the United States have CF [9] and it is 
estimated that more than 10 million people in the United States are carriers of mutated 
CFTR [10]. The birth prevalence of CF is one in 3500, and there are approximately one 
thousand new cases per year [9]. It is estimated that 10% of the thousand CF cases 
diagnosed per year are in adolescents and adults [7]. 
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Andersen published the first clinical description of CF in 1938, describing infants 
suffering from malabsorption and pancreatic fibrosis who developed pulmonary 
dysfunction with age [3, 11]. Diagnosis of CF in the early 1900’s was based entirely on 
clinical symptoms and the life expectancy was approximately six months [4]. A 
diagnostic breakthrough for CF occurred in 1959, when Gibson and Cooke developed the 
sweat chloride test for CF, after Darling and co-workers noted that patients suffering 
from CF have a higher than normal concentration of sodium and chloride in their sweat 
[12]. In 1985, Knowlton mapped the genomic location of the CF locus to chromosome 
seven [13], and Rommens published a physical map of the region on chromosome 7 
where the cystic fibrosis gene locus was located [14]. This led to the discovery by 
Riordan, in 1989, who published the genomic sequence of the CF locus, and postulated 
that the gene product, CFTR, was a transmembrane protein, believed to contain ATP 
binding domains [15]. Riordan also identified the first known CFTR mutation, the F508 
deletion (deletion of a phenylalanine residue at codon 508), in this same paper [15]. 
Today, there are more than 2000 mutations of the CFTR gene identified in the CFTR2 
(Clinical and Functional Translation of CFTR) Cystic Fibrosis database [16]. The first 
discovered mutation turned out to be the most common mutation associated with CF: 
87% of CF patients are heterozygous for the F508 deletion mutation, and 46.5% of CF 
patients are homozygous for the F508 deletion [17]. Originally it was thought that there 
would be a clear relationship between a patient’s CF genotype and their clinical 
phenotype. However, much to the dismay of clinicians and scientists, the mechanism that 
determines CF severity is more complex. There are numerous genetic modifiers and 
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environmental factors that regulate the expression and severity of the clinical CF 
phenotypes [18].  
A classical case of CF is described as a monogenic disorder resulting from two 
CF mutations [18]. A patient typically presents prior to age two with a clinical triad of 
symptoms including chronic sinopulmonary infections, steatorrhea (high fat content in 
stool), and failure to thrive [18]. Approximately 85% of CF patients are pancreatic 
insufficient due to a loss of pancreatic exocrine function resulting in malnutrition [18]. If 
untreated, death is likely within the first decade of life [5]. However, if a patient is treated 
with pancreatic replacement enzymes and proper respiratory therapies, the median 
survival age in a classical CF case is now 41.1 years [9]. Obstructive lung disease is the 
primary cause of death in over 80% of classical CF cases [19]. 
While there is usually no debate over a classical CF diagnosis, since the 1960’s 
physicians have described a group of patients with less severe symptoms believed to have 
a different form of CF [4, 20]. Unlike patients’ suffering from the classical phenotype, 
these patients usually have one severe CF mutation on one chromosome, and one less 
common, mild CF mutation on their other chromosome; or one severe mutation of CFTR 
on one chromosome, and an abnormal number of trinucleotide repeats in the CFTR gene 
on their other chromosome [4, 6, 18, 21]. These patients, described in the literature as 
suffering from non-classical CF, late onset CF, CFTR- related disease, or atypical CF, 
represent a diagnostic challenge for physicians, and are often misdiagnosed [4]. Patients 
suffering from atypical CF usually only have one organ system that is dysfunctional, and 
their clinical symptoms may be less severe than those of a classical case where there are 
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two severe CF mutations [3, 4, 6, 22, 23]. Symptoms include bronchiectasis, chronic 
sinus disease, congenital bilateral absence of the vas deferens (CBAVD), and idiopathic 
pancreatitis [24, 25]. Further, unlike in classical disease, patients with atypical CF are 
generally pancreatic sufficient [24]. Patients with atypical CF are often not diagnosed 
until adolescence or adulthood [18, 20] due to the fact that the clinical symptoms in an 
atypical CF case develop and worsen over time [26]. This makes early diagnosis difficult 
[27].  
Although a patient diagnosed with atypical CF has a longer life expectancy and 
less severe clinical outlook than a patient with classical CF [22], early diagnosis at the 
onset of symptoms is imperative in yielding a good clinical outcome for patients. A delay 
in the diagnosis of atypical CF can result in hospital admissions and morbidity that 
otherwise could have been avoidable [4, 28]. Patients with atypical CF can be treated 
with chest physiotherapy, antibiotics, dietary modifications, and pancreatic enzyme 
replacements [3] that can slow the worsening of symptoms, and yield a favorable clinical 
outcome. With that said, the long-term outcome and life expectancy is unknown for 
patients suffering from atypical CF [4]. 
The purpose of this review is to summarize the current literature on the atypical 
form of CF in order to increase physician awareness and knowledge of atypical CF and 
decrease the number of missed diagnoses of atypical CF, thereby improving patient 
outcomes. The CFTR transporter structure and function and common mutations in both 
classical CF and atypical CF will be described so that a clinician can make sense of a 
mutation found in one of their patients; the signs and symptoms of atypical CF will be 
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described in detail and compared to those of classical CF; a case study will be presented 
to illustrate the difficulty in diagnosis as well as the diagnostic tools available, and finally 
current and future management options will be discussed. 	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PART 1: THE CFTR TRANSPORTER 
A) CFTR Protein Structure: 
The CFTR gene (OMIM 219700) is located at 7q31.2 and encodes a chloride 
channel at the apical cell surface, which is regulated by cAMP dependent 
phosphorylation [2]. The CFTR gene is comprised of 27 exons, which encodes a 6.5 kb 
mRNA transcript [29]. Dysfunction in the CFTR protein can cause the CF phenotype, or 
phenotypes other than CF [5]. The CFTR protein channel is a 1480 amino acids 
membrane spanning glycoprotein with a molecular weight of 170,000 kDa, and is a 
member of the ATP binding cassette superfamily [30]. The protein contains three primary 
motifs: two membrane-spanning domains (MSD1, and MSD2), two nucleotide-binding 
domains (NBD1, and NBD2), and a regulatory domain (R) [5]. The two membrane 
spanning domains are connected via a nuclear binding factor, which binds to ATP, and a 
regulatory region [30]. The regulatory region is unique in that it is not found on other 
members of the ABC superfamily [30]. A simplified illustration of the structure of the 
CFTR protein channel is depicted in Figure 1 along with brief description of the roles of 
the important structures. 
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Figure 1: CFTR Protein Structure 
 
Image created by [30]: 
http://www.genet.sickkids.on.ca/CftrDomainPage.html?domainName=NBD1 
Note: the cell cytoplasm is located on the inferior portion of the depicted 
membrane and the extracellular fluid is located on the superior portion of the membrane. 
R Region: Is encoded by exon 13 of the CFTR gene and contains cAMP 
dependent Protein Kinase A or C phosphorylation sites [30]. The channel opening 
probability depends on phosphorylation of the R region and on binding of ATP to NBD1 
and NBD2 [5, 30]. Amino acid residues 590 to 831 make up the R region [30]. 
NBD1 Region: This region binds to and hydrolyzes ATP, and controls the gating 
of the channel. Many CF causing mutations are located in this region. For example, the 
F508 deletion mutation is located here [30]. Amino Acid residues 433 to 584 make up the 
NBD1 region [30]. 
Transmembrane Domains: Two membrane spanning domains, each with six 
membrane-spanning regions, form the pore of the channel and subsequently regulate pore 
function. There are six positive charged amino acid residues within each transmembrane 
region [30]. Mutations in this region can lead to CF. For example, the R334Q/W 
mutation and R347L mutation are found in the first transmembrane domain [30]. The first 
membrane spanning region is made up of amino acid residue’s 82 to 351 and the second 
membrane spanning region is made up of amino acid residue’s 880 to 1149 [30]. 	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B) The Basic Problem – How Dysfunctional CFTR Causes Problems: 
Dysfunction in the CFTR chloride channel leads to abnormal viscous secretions 
and fluid flow in tubular organs including the lung, pancreas, liver, gastrointestinal tract 
and genitourinary system. Here, the mechanism of disease is explained in the lung and 
the pancreas—the two most prominent organs affected by CFTR mutations.  
1) Mechanism of lung dysfunction due to defective CFTR: 
Obstructive lung disease, due to chronic or repeated bacterial infections, 
inflammation, bronchiectasis (enlargement of walls of bronchi), or eventual lung fibrosis 
is the primary cause of death in 80% of all CF cases [5, 29]. Defective CFTR leads to 
decreased chloride ion transport and an increase in sodium transport, leading to a net 
increase in the absorption of water via the paracellular pathway across respiratory 
epithelium [29]. Summarized in Figure 2. 
CF most directly affects the upper respiratory tract, or the conducting portion of 
the lung. The epithelium of the upper respiratory tract is made up of a ciliated respiratory 
epithelium, containing low columnar or cuboidal shaped ‘club’ cells, which secrete a 
serous fluid, which traps particulates in the lung [31]. Together, the ciliated epithelium 
and secreted mucous protect against bacterial infection. The cilia beat at about 1000 times 
per minute in a coordinated manner to move the secreted mucus upward and out of the 
upper respiratory tract toward the pharynx [29]. 
As described in the prior section, the CFTR channel is activated by both the 
binding of ATP to NBD1 and NBD2 and by the phosphorylation of the regulatory 
domain. This allows chloride ion flow across the apical surface of the epithelium. 
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Activated CFTR also regulates other channels on the apical surface of the membrane. 
König, et al showed that active CFTR chloride channel inhibits the Epithelial Sodium 
Channel [ENaC] in the apical cell membrane [32]. In cystic fibrosis, where CFTR is 
dysfunctional, the ENaC channel is activated, and thus the cell absorbs more sodium and 
further stimulates the sodium potassium ATPase located on the basolateral membrane, 
which subsequently creates a net driving force for water absorption across the cell via the 
paracellular pathway [32]. In CF, there is a two to three fold increase in the net 
absorption of sodium across the respiratory epithelium [29]. This leads to a drier airway 
surface due to increased water absorption and to the impairment of proper cilia 
movement, which serves to clear out particulates and bacteria in the upper respiratory 
tract. The lung is now predisposed to infection, inflammation, bronchiectasis and fibrosis 
[29]. 
CFTR also has numerous other functions within the epithelial cell that likely 
contributes to clinical CF symptoms. CFTR regulates phagosome acidification in 
macrophages, and thus alters the bacteriocidal activity of the innate immune system [33]. 
It also modulates ORCC (Outward Rectifying Chloride Channel) activity by an autocrine 
mechanism involving ATP [34]. Thus, activation of wild type CFTR can lead to further 
chloride ion transport across the apical membrane by the additive effect of activation of 
the ORCC. CFTR also regulates vesicle transport within cells, and regulates ATP 
superfamily channels [1]. 
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Figure 2: Wild Type versus CF CFTR Ion Transport in Respiratory Epithelium: 
 
 
Image adapted from CFmedicine.com [29]. In the upper image, wild type CFTR 
allows for proper ion balance and the maintenance of normal mucociliary clearance. 
Active CFTR inhibits the ENaC channel, maintaining the correct osmotic gradient so that 
the watery ‘sol’ layer (denoted with blue color) above the apical epithelium allows for 
proper movement of cilia [29]. The airway surface remains hydrated and proper 
mucociliary clearance occurs. 
In the lower image, CFTR is mutated and is nonfunctional. ENaC is activated and 
sodium absorption is increased two to three fold leading to an increase in water 
absorption from the ‘sol’ layer above the apical epithelium. The ‘sol’ layer becomes 
dehydrated, and the cilia cannot beat efficiently [29]. Proper mucociliary clearance is 
inhibited and bacteria accumulate in mucous layer leading to infection and inflammation. 
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2) Mechanism of Pancreatic Dysfunction Due to Defective CFTR: 
The majority of patients suffering from classical CF are also pancreatic 
insufficient due to loss of pancreatic exocrine function. This leads to malnutrition 
secondary to the inability to digest food. Figure 3, shown on the following page, presents 
a schematic of the ion channels present in a human pancreatic duct cell. 
Normally, the CFTR channel in pancreatic duct cells will permit chloride ion that 
entered the cell via the luminal chloride/bicarbonate anti-porter to diffuse back to the 
lumen. The diffusion of chloride ion back into the lumen makes the luminal potential 
more negative than the basolateral border, causing interstitial sodium to move through 
paracellular pathway through the duct cells into the lumen [36]. Further operation of the 
chloride/bicarbonate anti-porter leads to a build up of bicarbonate and sodium movement 
into the lumen. Water follows the ion movement into the lumen, creating a large volume 
of an alkaline solution. 
In CF, the chloride channel is non-functional. This prevents the creation of a large 
volume of alkaline NaHCO3 fluid and causes protein aggregation and blockage of the 
ductal lumen [36]. The lower volume of alkaline fluid produced in the absence of CFTR 
cannot flush mucus and the protein aggregates out of the ducts [36]. Thus, enzymes are 
not secreted into the small intestine to facilitate proper digestion, which leads to 
malabsorption. Pancreatitis occurs if trypsin is activated in the pancreatic duct, which 
results in the activation of other precursor digestive enzymes [36]. 
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Figure 3: Pancreatic Duct Cell and CFTR [35] 
  
Image provided by http://ajpcell.physiology.org/content/276/1/C16 [35] 
A schematic of the ion transporters present in human pancreatic duct cells is 
displayed above. 
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C) Mutations in the CFTR Gene: 
As of August 2015, more than 2,000 mutations in the CFTR gene have been 
entered into the CFTR2 database, comprising of data from 88,664 patients [16]. 
According to Cutting in his 2014 review of cystic fibrosis genetics: 40% of CFTR 
mutations are a result of a substitution of a single amino acid; 36% of CFTR mutations 
alter mRNA processing due to a nonsense, frameshift, or splice sequence alteration; 3% 
of CFTR mutations involve a large rearrangement of the CFTR gene; 14% of variants are 
neutral variants and do not cause CF; and 6% of CFTR mutations have an unclear effect 
[5]. 
The CFTR2 database classifies mutations in CFTR as either CF causing, non-CF 
causing, a mutation of varying clinical consequence, or a mutation with an unknown 
clinical effect [16]. Mutations in CFTR are considered CF causing by the Cystic Fibrosis 
Foundation if they fulfill one of the following criteria: they must (1) change the sequence 
of CFTR in a way that affects protein synthesis and function; or (2) introduce a 
termination sequence via a mutation; or (3) change an intron splice site; or (4) form a new 
amino acid sequence that is not present in gene carriers of patients ethnic group [37]. 
In the literature, six classes of CFTR mutations are described. A summary of 
these mutations is listed in Table 1.  
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Table 1: Summary of CFTR Mutation Classes 
  Class I Class II Class III Class IV Class V Class VI 
Defect in 
CFTR 
Defective 
protein 
synthesis 
resulting in 
no 
functional 
protein 
Protein is 
not 
trafficked 
to apical 
membrane 
Regulation 
of Channel 
opening is 
defective 
Defect in 
Conductance 
of Channel 
Decreased 
Functional 
CFTR 
Synthesis 
Decreased 
Membrane 
Stability of 
CFTR 
Type of 
mutation 
nonsense, 
frameshift, 
splice 
variant 
missense, 
deletion 
missense, 
AA change 
missense, AA 
change 
Splicing 
variant, 
missense 
missense, 
AA change 
Example G542X F508del G551D R117H 5T allele Q1412X 
Table generated with information from [3, 18, 38] 
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Although widely accepted in the CF literature, these classifications have been 
criticized because certain mutations have varying effects and can fit into multiple 
categories. For example, the F508del mutation, which is an out of frame deletion of -
CTT- nucleotides [39] causes: 1) a low membrane residency of CFTR (Class VI 
mutation) [5]; 2) a silent codon change (ATC->ATT) in the triplet that encodes isoleucine 
at codon 507 [39], leading to a decrease in translation efficiency (Class V); and 3) 
disrupts proper CFTR trafficking to the membrane (Class II) [5]. 
To get classical CF a patient must have two severe mutations which are usually 
considered as class I, II or III [17]. Patients with atypical CF typically have on severe 
mutation and at least one mild mutation typically of class IV or V, that allows for the 
residual function of CFTR -thus, their disease is not as severe [7]. It is accepted that 
patients with less than 1% of wild type CFTR function have the classical form of CF 
characterized by pancreatic insufficiency and chronic pulmonary infections [40]. Patients 
with less than 4.5% of wild type CFTR function display symptoms of progressive 
pulmonary dysfunction, and patients with less than 5 percent of wild type CFTR function 
have a sweat chloride measurement abnormality [40]. Less than 10% of wild type CFTR 
results in the CBAVD in males [40]. Currently, researchers with CFTR2 are developing a 
computer algorithm to match CF genotype to disease symptoms [16]. 
To illustrate the differences in genotype between classical CF and atypical CF, a 
2005 study by Rodman [41] compared the genotype distribution of 55 patients that were 
either diagnosed early in life (below age 15) with CF or diagnosed with CF later in life 
(age greater than 24). All of the patients in the study were older than 40. The genetic 
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distribution of the patients is shown in Table 2. Note that patients in the late diagnosis 
group had a higher prevalence of class III-V mutations and unidentified mutations, and 
that homozygous individuals were more common in the early diagnosis group.  
Rodman’s observations are also supported in a study by Nick, who found that 
70% of long surviving patients had one residual function (class IV or V) mutation [11]. 
The results of Rodman’s study indicated that patients in the late diagnosis group had 
clinical symptoms that were milder, and indicative of atypical CF. Another interesting 
finding not indicated in the table was that the majority of patients in the late diagnosis 
group were female [41]. 
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Table 2: Genotype Distribution in Patients with Early and Late Diagnosed CF [41] 
 
Aside from the specific mutations in CFTR themselves, some mutations may be 
made more or less severe depending on a genetic variant located on the same 
chromosome [40]. One example is the poly-thymidine tract in intron 8, which is situated 
near the splice site on exon 9 [42]. Three variants exist, including the 5T, 7T and 9T 
alleles [40]. Variation in the number of thymidine nucleotides can result in a decreased 
amount of normal CFTR mRNA [42]. The 5T allele is the most severe of the three 
mutations, and the 9T allele maintains the most function at the splice site [42]. These 
genetic variations of the poly-thymidine tract are particularly important in atypical CF. 
For example, the R117H mutation clinical phenotype depends on what poly-thymidine 
624 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 171 2005
Figure 5. Differences in lower airway pathogens. P. aeruginosa (all forms)
and mucoid P. aeruginosa was more prevalent in the ED group (white
bars), whereas S. aureus, B. cepacia, and Aspergillus species had equal
prevalence in both groups. In contrast, the prevalence of nontubercu-
lous mycobacteria (NTM) recovered, and NTM infection (defined by
American Thoracic Society criteria) was greatest in the LD group (solid
bars). Patients older than 40 years enrolled in the CFF patient registry
(hatched bars) had a similar prevalence of P. aeruginosa, but positive
cultures for NTMappearmuch less common. The percentage of patients
with CF who met criteria for NTM infection was not available (N/A).
Plot depicts percentage of patients with at least one positive culture
for each organism; *p ! 0.05 by Fisher’s exact test.
our study had a similar prevalence ofP. aeruginosa and S. aureus.
A lower percentage of CFF registry patients had positive cultures
for B. cepacia, Aspergillus species, and NTM. However, the
requirement for special culture techniques for NTM may have
resulted in an underrepresentation of actual prevalence.
TABLE 1. GENOTYPE DISTRIBUTION
Early Diagnosis Late Diagnosis
"F508/"F508 10 1
"F508/"I507 1
"F508/G551D 1
"F508/M1101K 1
"F508/P67L/11027T 1
"F508/3120G-A 1
"F508/2789#5G-A 1 2
"F508/W1282X 1
"F508/621#1G-T 1
"F508/R347P 1
"F508/3849#10kbC-T 1 1
"F508/A455E 2
"F508/R347H 2
"F508/D1152H 1
"508/I148T 1
"F508/R117H 1
"F508/Y109N 1
"F508/IVS8–5T 1
"F508/unknown 3 5
S1251N/D1152H 1
G542X/R117C 1
R117H/G551D 1
W1282X/D1152H 1
Unknown 4 4
Values represent number of individuals in each diagnostic group with each
genotype.
DISCUSSION
As the CF population ages and testing for rare CFTRmutations
has becomewidely available, increased attention has been placed
on the late diagnosis of the adult patient. Several series describ-
ing characteristics of younger adult patients, including those
diagnosed after childhood, have been published in the last de-
cade. McCloskey and coworkers (12) described 18 patients with
CF (aged 14–36 years) diagnosed after age 10 in Northern Ireland.
Gan and coworkers (13) reported on 25 patients with CF (aged
21–55 years) in the Netherlands diagnosed after age 16, with a
median age at diagnosis of 27 years and a mean age of 35.7
years. An analysis of the CFF patient registry data from 1996
by Widerman and colleagues (14) identified a cohort diagnosed
after age 18, with a mean age at diagnosis of 27 years. Although
these reports describe populations of LD patients with CF who
were diagnosed 20 to 30 years earlier than the LD group in this
report, the investigators’ findings support the conclusions of this
study. Specifically, patients with CF diagnosed after childhood
have less severe lung disease, are more likely to have pancreatic
sufficiency, have a lower prevalence of P. aeruginosa, and have
a lower prevalence of the "F508 mutation (12–14).
CF is a monogenic, autosomal-recessive, inherited disorder.
Before identification of the disease locus, CFTR, it was widely
assumed that much of the variability in disease phenotype would
be explained by functional differences in specific disease-gene
mutations (19). Although this assumption has proved to be gen-
erally true, in certain individuals profound differences have been
observed between actual and predicted disease severity based
on the class of CFTR mutation (6). In these patients with CF,
the lack of a tight phenotype–genotype correlation can be ex-
plained by two hypotheses: (1) differences in environmental
cofactors and (2) expression of modifier genes at other loci.
These hypotheses are not mutually exclusive.
The testing of these hypotheses requires identification of sub-
populations of affected individuals who have significantly differ-
ent clinical phenotypes. The long-term survivors of CF, defined
for the purposes of this study as 40 years or older, represent the
oldest 5% of individuals nationally and appear to be an impor-
tant population to study factors that allow for increased survival.
Two relatively distinct subpopulations were apparent within the
long-term survivor group. One group, referred to as “ED,” had
a median age at diagnosis of 2 years and a second population,
referred to as “LD,” had a median age at diagnosis of 48.8 years.
Thus, for the purposes of this study, the ED group was defined
as age at diagnosis of less than 15 years, and the LD group was
defined as age at diagnosis of more than 24 years.
Several limitations of using age at diagnosis as a discriminate
variable should be acknowledged. In addition to differences in
phenotype, delay in diagnosis may be influenced by a variety of
nonclinical factors, such as access to, and quality of, health care,
the ability to tolerate symptoms, and implementation of newborn
screening. Although newborn screening is too recent a develop-
ment to have affected our study population, in the future, newborn
screening (and prenatal screening) may decrease the proportion
of individuals diagnosed at later ages, thus limiting the ability to
use this variable to discriminate discrete subpopulations of CF-
affected individuals (20).
An analysis of diagnostic testing, including CFTR genotype,
showed that the average sweat chloride value, loosely correlated
to the presence of missense mutations, was slightly lower in the
LD group (21). However, in part because of the entry criteria
established for this study, all but two individuals had a diagnostic
sweat chloride test. Other individuals in our center’s database
had a clinical syndrome consistent with CF: a borderline sweat
chloride value and one CFTR mutation identified. Although
	  18 
allele is present. When R117H is on the same chromosome as the 7T allele, a patient will 
likely have adult diagnosed CF, pancreatic sufficiency, and either mild or chronic lung 
disease [7]. However, when R117H and the 7T allele are on opposite chromosomes, a 
patient may experience mild CF or no symptoms at all [7]. In this case, other factors such 
as genetic modifiers or the environment likely contribute to the development of CF 
disease like symptoms. 
D) Genotype-Phenotype Correlation and Variation in Disease Severity: 
Upon the initial discovery of the CFTR gene in 1989, it was thought that the 
phenotypic variability of symptoms observed in CF patients would be entirely attributed 
to the allelic heterogeneity in the dysfunctional CFTR gene [43]. The scientists who 
originally discovered CFTR also thought that there could be as many as 10 mutations 
[44]. Both predictions turned out to be false. 
The clinical possibilities of a patient with two CFTR mutations are immense: 
Some possibilities include: (1) patients who have no symptoms of CF and normal sweat 
chloride levels, (2) patients with classic CF symptoms, (3) patients with sinopulmonary 
disease, positive sweat chloride tests and pancreatic sufficiency, (4) patients with 
sinopulmonary disease, normal sweat chloride tests, and male fertility, (5) patients whose 
only symptom is male fertility, (6) patients with chronic sinusitis and CBAVD, (7) 
patients with chronic pancreatitis only, (8) patients with positive sweat chloride tests 
only, and no symptoms [44]. With this variety of presentations, it is no surprise that 
diagnosis of the atypical presentations of CF is difficult. A possible conclusion that can 
be drawn from the variety in clinical presentations is that although CF is a disorder 
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caused by a single gene, its clinical presentation resembles that of a polygenic disorder 
[44] and that genetic modifiers and environmental factors likely play a large role in 
determining the severity of CF symptoms. 
Although CFTR genotype correlates with the overall severity of pancreatic 
exocrine disease, and to sweat chloride levels [45, 46], genotype does not correlate with 
pulmonary disease severity [45, 47]. To attempt to elucidate links between pulmonary 
disease severity and genotype, the European CF Twin and Sibling Study, compared 
affected monozygotic twins to affected dizygotic twins. It was found that CF affected 
monozygotic twins had a significantly lower DELTA value (a parameter used by the 
researchers to define disease severity) than dizygotic pairs, suggesting that CF disease 
severity is modulated by an inherited component (genetic modifier) in addition to the 
gene itself [48]. In another study using affected monozygotic twins and sibling pairs, it 
was found that 50% of the variation in pulmonary function between twin and sibling pairs 
could be attributed to genetic modifiers, while 36% of variation could be explained by 
environmental factors unique to the individual, and 14% to shared environment [49]. 
Thus, genetic modifiers and the environment likely affect the severity of CF pulmonary 
disease. 
E) What are the Genetic Modifiers? 
Genetic modifiers are genes not found within the CFTR gene, which modify the 
expression of the CFTR gene. Some genetic modifiers to clinical CF phenotypes are 
presented below, however, many more have been identified in the literature and more are 
being discovered every year. 
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1) A major determinant of CF lung disease severity is inflammation, and it is 
likely that the inflammatory system influences the pulmonary phenotype in those who 
have CF [50]. One possible effector is TGFβ-1 (transforming growth factor β 1). 
Polymorphisms of the TGFβ-1 gene have been shown to lead to variations in cytokine 
levels and are linked to fibrosis in various tissues [51]. In one study by Arkwright, 
patients with CF and a high producing TGFβ-1 genotype had more pronounced 
deterioration in lung function than those with the low TGFβ-1 producer genotype [51]. 	  
Another example of a possible effector of inflammation is mannose-binding lectin 
(MBL), which is a component of the innate immune system. One study found that the 
presence of the MBL variant allele is associated with poor prognosis and early death in 
patients with CF [52]. Another study showed that MBL variant alleles may make some 
CF patients more susceptible to recurrent infections, and that lung function in patients 
with the MBL variant allele may be reduced compared to wild type [53]. 
2) Colonization of lungs by Pseudomonas aeruginosa is associated with reduced 
survival in CF patients and is considered a hallmark of progressing lung disease [5]. A 
study by Green showed that genetic factors influence the age at the establishment of 
chronic infection with Pseudomonas aeruginosa [54]. 
3) Meconium ileus (MI) is an obstruction of the small intestine, and is found in 
10-15% of CF patients in utero or in early neonatal period [44]. There is evidence of a 
modifier locus for MI on chromosome 19q13, providing evidence that there is a gene that 
predisposes a carrier to have meconium ileus in combination with CF [55]. 
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4) For patients with classical CF, poor growth is caused due to pancreatic 
exocrine dysfunction. Although replacement enzymes can be administered there is still a 
cohort of patients with a low BMI even with therapy [5]. Genetic control of BMI without 
considering the effect of CFTR seems to be important in this case [5]. 
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PART 2: CF AND ATYPICAL CF SIGNS AND SYMPTOMS 
Clinical symptoms of both classical and atypical cystic fibrosis are largely 
restricted to the respiratory, gastrointestinal, endocrine, and genitourinary tracts. 
Symptoms are broken down by organ system for classical CF, and atypical CF, 
respectively, so that one can compare the two presentations of the disease. A discussion 
of frequent mutations associated with clinical symptoms of atypical CF is also included. 
Classical CF: 
Patients suffering from classical CF tend to present prior to age two with a clinical 
triad of symptoms including chronic sinopulmonary infections, steathorrhea, and failure 
to thrive. Classical symptoms are associated with two severe class I-III CFTR mutations 
on two separate chromosomes.  
1) Symptoms in the respiratory tract: Respiratory symptoms are the primary 
association a physician has with CF Fibrosis for good reason; pulmonary dysfunction 
contributes to 80% of CF mortality and morbidity [5]. Symptoms associated with 
classical CF include the following: chronic or recurrent sinopulmonary infections, 
colonization of lungs by pseudomonas aeruginosa, bronchiectasis, nasal polyposis, 
refractory asthma, and symptoms of progressive respiratory obstruction -- all of which 
begin in childhood [56]. Interestingly, the presence of digital clubbing is associated to the 
degree of hypoxemia, and airway obstruction [57]. 
2) Symptoms associated with the gastrointestinal tract: Approximately 85% of 
classical CF patients are pancreatic insufficient. Symptoms of exocrine pancreas 
insufficiency include steatorrhea (presence of high fat content in stool), fat-soluble 
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vitamin deficiency, and difficulty gaining weight [28]. Other symptoms involve liver 
cirrhosis, and portal hypertension. Approximately 20% of affected children between the 
ages of 6 months and 3 years suffer from rectal prolapse secondary to malabsorption, 
elimination of bulky stools, and poor muscle tone [18]. Salt bile depletion syndrome 
manifested as hypokalemia or metabolic alkalosis has been reported as well as prolonged 
neonatal jaundice due to intrahepatic bile stasis [18]. 
3) Symptoms associated with the genitourinary tract: Approximately 97 to 98% of 
men with classical cystic fibrosis suffer from azoospermia in a semen sample due to 
congenital bilateral absence of the vas deferens (CBAVD) [4, 59, 60]. Women are 
generally fertile but can experience difficulty in conceiving a child due to thickened 
cervical mucus [61, 62].  
4) Symptoms associated with endocrine and metabolic organ dysfunction: 
In classical CF, patients can suffer from endocrine pancreatic dysfunction. One paper 
suggests that this can even be the primary presentation of CF [63]. Other symptoms 
include electrolyte imbalances, which mostly occur due to dehydration or a heat stroke 
[4, 21]. 
5) Other symptoms: Other symptoms indicative of classical CF include dermatitis 
caused by nutritional deficiencies, early aqueous wrinkling and angititis [4]. 
Atypical CF: 
Atypical CF symptoms are in general less severe and subtler than the classical CF 
symptoms associated with the same organ. For atypical cases, it is likely that dysfunction 
is in only one organ system, and that symptoms worsen over time [3, 4, 6, 22, 23]. 
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Patients suffering from atypical CF usually have one severe CFTR mutation and one 
mild, residual function CFTR mutation, or one severe mutation along with an 
abnormality in trinucleotide repeats on their other chromosome [4, 18, 21]. The most 
common mutation found in adult diagnosed patients with atypical CF is the F508del, 
followed by R117H, 3849+10kb C to T, and the D1152H mutation [7, 64]. In one study 
[22] examining the genetics of patients diagnosed with CF in adulthood, there were no 
homozygous F508del mutations found, but 72% were heterozygous for F508del and 28% 
had two other mutations aside from F508del. A summary of symptoms associated with 
atypical CF is located in Table 3 and the clinical presentation of symptoms at the time of 
diagnosis broken down by age group is located in Table 4. 
1) Symptoms Associated with respiratory tract: Approximately 70% of patients 
diagnosed after the age of 18 years initially presented to their clinician with acute 
respiratory symptoms [64]. Respiratory symptoms associated with atypical CF are 
generally milder when compared to symptoms of classical CF and may not begin until 
adulthood (4). Symptoms include recurrent pneumonia, and symptoms involving chronic 
obstruction of the airways including: COPD, chronic sinusitis, nasal polyposis, idiopathic 
(cause unknown) bronchiectasis and asthma [4, 18, 7, 65, 66, 67].  
Two studies by Rodman [41] and Nick [11] compared the FEV1 (forced 
expiratory volume in 1 second) measurements at age 40 of patients diagnosed with 
classical CF as a child to patients who were diagnosed with CF after age 18. Both studies 
showed that patients diagnosed with CF after the age of 18 (considered atypical CF) had 
better FEV1 measurements than patients who were diagnosed with classical CF in 
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childhood. FEV1 values for the childhood diagnosis group were 50% and 40% and FEV1 
values for the adult diagnosis group were 57.9% and 60% respectively in Nick’s and 
Rodman’s publications [11, 41]. Thus patients suffering from atypical CF likely have less 
severe lung dysfunction than those suffering from classical CF, but still worsened lung 
function compared to a non-CF patient. 
In 2010, Keating published an article in Chest analyzing the CF Foundation 
Patient Registry for patients diagnosed with CF after age 18 [64]. She found that 16% of 
patients diagnosed as adults have nasal polyps and sinus disease at their initial 
presentation. She also found a difference in the types of bacteria that colonize the lung in 
classical CF and atypical CF cases: for patients less than 12 years old, 27% had 
colonization with Pseudomonas aeruginosa, and less than 0.1% suffered from non-
tuberculosis mycobacterium avium complex (MAC) infection, while patients with adult 
diagnosed patients had 50%, and 5% colonization respectively [64]. 
2) Symptoms associated with the GI tract: GI symptoms are rarer in atypical CF 
than in classical CF. Symptoms include chronic constipation, diarrhea [4, 65, 68] and 
recurrent idiopathic pancreatitis with no respiratory symptoms [4, 7]. Patients with 
atypical CF are also less likely to have steatorrhea [7].  
According to multiple studies, patients with atypical CF or adult diagnosed CF are 
less likely to be pancreatic insufficient than patients with classical CF who were 
diagnosed in childhood [11, 69, 70]. Nick’s study showed that 50% of adult diagnosed 
patients that lived to at least 40 years had pancreatic sufficiency [11]; thus we cannot rely 
on pancreatic insufficiency alone for a CF diagnosis in adults [7]. However, idiopathic 
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pancreatitis, without any other CF symptoms is indicative of atypical CF. According to 
Boyle [7], 10-15% of patients with idiopathic pancreatitis that do not consume alcohol or 
have gallstones have a mild form of CF. 
3) Symptoms associated with the endocrine organs: Diabetes mellitus and 
electrolyte imbalances are the two symptoms associated with atypical CF [4]. 
Interestingly, type two diabetes mellitus (T2DM) is associated with rapid decline in lung 
function in patients suffering from classical CF [5]. 
4) Symptoms associated with the genitourinary tract: As described in the classical 
symptom section, 97-98% of men with classical CF are infertile due to CBAVD. One in a 
thousand men suffer from CBAVD in the total population, which is the cause of 1-2% of 
total male infertility cases [18]. 
CBAVD presents an interesting case of CFTR genetics: in men with CBAVD 
alone, 10-20% carry two CFTR mutations, 40-60% carry one CFTR mutation, and 30-
50% have no CFTR mutation [6]. CBAVD is typically caused by a residual function 
CFTR class IV or V mutation, resulting in less than 10% of wild type CFTR function 
[18]. These mutations are likely splice variants or missense mutations, commonly the 5T 
allele and the R117H mutation [7, 18, 44, 71]. However, it is interesting that individuals 
with the same genotype do not necessarily have the same clinical phenotype. For 
example, for a male individual with one copy of the F508del on one chromosome and the 
5T allele on the other chromosome: 40% of the time there will be no disease, 60% of the 
time only CBAVD will be present, and less than one percent of the time atypical CF will 
occur [7, 72]. Another study [73] found that patients with CBAVD who were otherwise 
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normal had an increased likelihood of suffering from mild to moderate respiratory 
disease. Together the results of these studies suggest that CBAVD is associated with 
CFTR mutations, with atypical CF and that mild symptoms take time to develop. A 
prospective study following patients with CBAVD, and two CFTR mutations from their 
time of diagnosis through their 50’s could more closely reveal a relationship between 
CBAVD and the temporal development of symptoms representative of atypical CF. 
Genetic modifiers and environmental factors also likely play a role in development of 
atypical CF in these patients. 
In summary, a physician should consider that a patient is suffering from atypical 
cystic fibrosis if bronchiectasis is observed along with any of the following: idiopathic 
pancreatitis, CBAVD, MAC infection, Pseudomonas aeruginosa infection, allergic 
bronchopulmonary aspergillos infection, sinus disease or nasal polyposis [7].  
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Table 3: Summary of Symptoms associated with atypical CF Adapted from [4, 7 18, 64, 
65, 66, 67] 
Organ System Symptoms 
Respiratory 
chronic sinusitis, COPD, nasal polyposis, recurrent pneumonia, 
idiopathic bronchiectasis, asthma, Pseudomonas aeruginosa 
colonization, MAC colonization 
GI 
diarrhea, constipation, idiopathic pancreatitis, weight loss, nutritional 
deficiency 
Genitourinary CBAVD in males, reduced fertility in females 
Endocrine Diabetes mellitus, electrolyte imbalances 
 
Note that any symptom of CF could be a symptom of atypical CF. The most common 
symptoms of atypical CF identified in the literature are listed in the Table 3 above. 
 
 
Table 4: Clinical Presentations at the Time of Diagnosis. Table adapted from [64]. 
 
*Other: Includes idiopathic pancreatitis and male infertility. Patients diagnosed prior to 
age 12 likely present with the classical form of the disease and patients diagnosed after 
the age of 18 represent the atypical presentation of CF. 
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PART 3: DIAGNOSING ATYPICAL and CLASSICAL CYSTIC FIBROSIS 
Diagnosis of classical CF is well characterized and is usually undisputed. The CF 
Foundation Consensus Criteria for Diagnosis includes the following: a patient must 
exhibit clinical symptoms of CF (listed in prior section), a family history of CF, or a 
positive newborn screen test for CF [3]. Also, a patient must have evidence of abnormal 
CFTR function depicted by a sweat chloride level greater than 60mmol/L, a genetic test 
result showing two mutations in CFTR, or abnormal nasal transepithelial ion transport [3, 
44]. 
A 2006 review article on cystic fibrosis diagnostic algorithms [56] published in 
Thorax recommends that a physician who suspects that a patient has CF start with a 
sweat chloride test. A sweat chloride test yields strong evidence for the clinical presence 
of cystic fibrosis. Traditionally, a sweat chloride value of greater than 60mmol/L is 
indicative of CF [3,74]. If the sweat chloride value is greater than 70mmol/L, the 
specificity and sensitivity of the sweat chloride test approaches 100% [75]. Patients with 
this level of sweat chloride will nearly all have two severe CF causing mutations. 
However, follow up testing is still recommended until a genetic confirmation can be 
obtained [74]. Conversely, a sweat chloride value below 39mmol/L is unlikely to be CF 
[3], and a value between 40-59mmol/L is considered intermediate [74]. 
It is in a patient who has a sweat chloride level in the intermediate range that 
could have atypical cystic fibrosis. For these patients, who are usually adolescents and 
adults that did not receive newborn CF screening, follow up genetic testing and nasal 
potential difference testing is recommended. Today, these patients make up roughly 10% 
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of those diagnosed with cystic fibrosis [7]. An article published in Chest in 2010 by 
Keating determined that 8.3% of new CF diagnoses occurred in patients over the age of 
18, and that the proportion of CF diagnoses in patients over 18 years of age has been 
increasing every year [64]. It is likely that this number will continue to rise until all 
patients born before newborn screening have been diagnosed. According to Keating, 25% 
of adult patients diagnosed with CF, have indeterminate sweat chloride concentrations 
[64]. 
Follow up genetic testing is performed in patients with intermediate sweat 
chloride levels. Patients identified with two mutations in CFTR on separate chromosomes 
that are known to cause CF can be diagnosed with atypical CF [56]. In patients with 
borderline or intermediate sweat chloride levels and one or zero CFTR mutations, nasal 
potential difference testing is performed [4, 56]. This is because the patient may have a 
novel CFTR mutation, or a mutation that was not screened for in the genetic test. A flow 
chart of the process of CF diagnosis is provided in Figure 4. 
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Figure 4: A Diagnostic Algorithm for CF [42] 
A flow chart depicting the diagnosis of atypical CF starting with a sweat test. 
Individuals with intermediate sweat chloride test results are tested twice and then tested 
for genetic mutations in CFTR. If two CF causing mutations are identified, atypical CF 
can be diagnosed. If only one mutation is identified, a nasal potential difference test is 
performed. An abnormal result provides evidence for atypical CF diagnosis. If the nasal 
potential difference test is normal, CF is unlikely. 
classified as ‘‘mild’’. Some patients with single organ involve-
ment resulting from CFTR dysfunction may be more appro-
priately given an alternative ‘‘diagnostic label’’ as recommended
in the World Health Organization (WHO) diagnostic list
(table 1).2 In these cases the importance of identifying a CFTR
mutation may be greater for the family (for genetic counselling
reasons) than for the index patient.
‘‘Classic’’ and ‘‘typical’’ CF are considered synonyms; the
same applies to ‘‘non-classic’’ and ‘‘atypical’’ CF. In the
current document the terms ‘‘classic’’ and ‘‘non-classic’’ will
Clinical suspicion
Sweat test
CF centre
Repeat sweat test
CFTR DNA test
Nasal PD
CFTR DNA test
Consult
genetic lab
Mutatation scanning
of CFTR gene
Inconclusive
Consider FU (at CF centre)
Consider
CF heterogeneity?
False + sweat test?
Consider alternative diagnosis
Appropriate investigations
and follow-up
Follow-up at CF centre
CF unlikely CFTR dysfunction
– non classic CF
– WHO diagnostic list
Classic CF
<30 mmol/l 30-60 mmol/l >60 mmol/l
<30 mmol/l 30-60 mmol/l >60 mmol/l
0 mutation
0 mutation 1-2 mutations
1 mutation 2 mutations
0 mutation 1 mutation 2 mutations
Clinical review
other diagnosis
Yes No
Normal Inconclusive Abnormal
Figure 1 Algorithm for the diagnosis of CF starting with the sweat test. When entering the algorithm it is advised to continue the diagnostic work up if
symptoms in a patient persist, as well as when symptoms have resolved but are highly suspicious for CF such as pancreatitis or Pseudomonas
aeruginosa lung disease. Wherever the algorithm ends with ‘‘CF unlikely’’ it is advised to inv stigate for alternative diagno es such as primary ciliary
dyskinesia, humoral immunodeficiency, Shwachman syndrome. For patients with CFTR dysfunction, the physician needs to decide the most appropriate
diagnostic label (non-classic CF or an item from the WHO diagnostic list shown in table 1 in patients with very limited symptoms). Patients with a
borderline sweat test (30–60 mmol/l), only one CFTR mutation identified, and an inconclusive nasal potential difference (PD) cannot at present be
classified correctly. They are at least CF carriers. In the presence of persistent symptoms they need structured follow up at an appropriate facility (for
some patients this may be the CF centre) and symptomatic treatment. Genetic counselling is important in these patients and their families. CFTR DNA
test: screening test to search for the most frequent mutations in the population from which the patient originates. Mutation scanning of CFTR gene: this
test is only necessary in som pat ents in whom the diagnosis cannot be supported by other means. The tests in the grey area are optional because two
clearly positive sweat tests are sufficient to support the diagnosis of CF in a compatible clinical setting. However, in most CF centres the CFTR DNA test
will be performed to confirm the diagnosis, to allow for further cascade screening if necessary, and at times for research purposes. Consult genetic lab:
in patients with an elevated sweat chloride level it would be unusual but not impossible not to find any mutation. In case of doubt about the diagnosis, a
mutation scanning of the complete gene can be done. A falsely positive sweat test and the possibility of CF heterogeneity also need to be considered.
628 De Boeck, Wilschanski, Castellani, et al
www.thoraxjnl.com
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Nasal potential difference testing can provide evidence to strengthen an atypical 
CF diagnosis, but is not a definitive test on its own [4]. It is a difficult test to perform and 
is only available in certain academic medical centers. Like sweat chloride levels, some 
patients suffering from atypical CF can have intermediate nasal potential difference 
levels [76]. In CF, the baseline potential difference is more negative than in patients with 
wild type CFTR [76]. When amiloride, an ENaC channel inhibitor, is added, sodium flow 
is disrupted and the potential difference increases (becomes more positive). In CF, there 
is a larger than normal increase in nasal potential difference due to aberrant regulation of 
the ENaC channel. The nasal mucosa is then washed with a chloride free solution, and 
lastly, isoproterenol is added. Figure 5 on the following page shows nasal potential 
difference tests on a healthy subject with wild type CFTR and a CF case. 
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Figure 5: Nasal Potential Difference Testing in Normal and CF Individuals [5642] 
 
Nasal potential difference testing is shown in a normal individual in A and a CF 
patient in B. The CF patient has a more negative baseline potential difference than the 
normal individual. Upon addition of amiloride, the potential difference increases toward 
zero in CF individuals at a higher rate than in the normal individual. Upon addition of a 
chloride free solution, the basal potential difference does not change in a CF individual, 
and decreases (becomes more negative) in a normal individual. Addition of isoproterenol, 
a β1 and β2-agonist, leads to an increase in intracellular cAMP and the activation of the 
CFTR channel. In normal individuals, a decrease in potential difference is seen, while 
there is no effect on the CF nasal potential difference [3]. In atypical cases, a borderline 
test result can be observed, with changes that are intermediate in nature between what is 
expected in a wild type CFTR individual and a CF individual [76]. There is not yet a 
consensus as to what constitutes a negative result [56]. 
 
 
 
Transepithelial nasal potential difference (nasal PD)
The use of nasal PD as a diagnostic test for CF is already
accepted in the diagnostic consensus of Rosenstein et al.5 The
test has been introduced in clinical practice in ma y large CF
centre that have compiled the r own reference values.
Several papers report on the usefulness of nasal PD
measurements for diagnosing CF.35–38
Nasal PD is determined by standard criteria as described by
Knowles et al.10 The PD is measured between a fluid filled
exploring bridge on the nasal mucosa and a reference bridge
on the skin of the forearm. The reference bridge may be
applied to the skin by a thin needle inserted subcutaneously
or placed directly on the skin after performing a small
abrasion. Practical details of this test have been published
elsewhere.10 39 With skilled operators and careful attention to
technical details, the nasal PD measurement can be used as
an outcome measure in therapeutic trials.40
The basal PD gives an indication of sodium transport via
the amiloride sensitive epithelial sodium channel. After
consistent baseline PD measurements have been obtained,
the effect of amiloride superfusion through a second tube
overriding the exploring catheter is evaluated. To study nasal
chloride permeability and cAMP activation of chloride
permeability, a large chloride chemical gradient is generated
across the apical membrane by superfusion of the nasal
mucosa for 3 minutes with a chloride free solution contain-
ing 1024 M amiloride in Ringer’s solution with gluconate
substituted for chloride at a rate of 5 ml/min. The same
solution to which isoproterenol 1025 M has been added is
perfused for a further 3 minutes. The change in voltage
response over the final 6 minutes serves as an index of cAMP
activation of epithelial chloride permeability.
The nasal PD of a patient with classic CF is remarkably
different from controls (fig 3). The basal PD is much higher
(more negative), the amiloride response is exaggerated, and
there is very little or no response to chloride free and
isoproterenol solutions. In non-classic CF the nasal PD may
be borderline and there is not yet a total consensus as to what
exactly constitutes an abnormal result, but a formula which
tak s into account both sodium and chloride transport has
been proposed.41
Intestinal current measurement (lCM)
The abnormalities in epithelial ion transport characteristic of
CF are also expressed throughout the intestinal tract. The
intestinal epithelium does not undergo infection induced
degenerative changes and is therefore suitable for use as a
functional test for the disease.42 As many intestinal ion
transport processes are electrogenic, measuring the electrical
current that they generate (intestinal current measurement,
ICM) can be used to monitor their activity. In CF, intestinal
chloride secretion is impaired while absorptive processes
remain unchanged and may even be enhanced.
Measurements can be performed on rectal43–45 or jejunal46
mucosa. There is a clear difference between ICM measure-
ment in classic CF and in normal individuals (fig 4). Data are
only now emerging about the use of ICM as a clinical
Figure 3 Nasal potential difference measurement in (A) a healthy
person and (B) a person with classic CF. In a healthy person the bas l PD
is negative (220 to 230 mV), rises moderately (towards zero) after
application of amiloride, and decreases after application of chloride free
solution and isoproterenol. In a patient with typical CF the baseline PD is
more negative and the rise after application of amiloride is greater.
There is no change in PD after applica on of chloride free soluti n and
isoproterenol.
µ
µ
µ µ
Figure 4 Intestinal current measurement in (A) a healthy person and (B) in a patient with classic CF. The responses to carbachol and histamine consist
of two components: a lumen positive current that is most likely caused by the apical potassium efflux and a lumen negative current caused by apical
chloride secretion. In ICM measurements of non-CF individuals the apical potassium efflux component in reaction to carbachol and histamine is masked
by the much larger chloride efflux. In CF the response is reversed due to the apical potassium efflux in the absence of a chloride efflux.
Terminology and diagnostic algorithms in CF 633
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Figure 5: A Diagnostic Algorithm for CF [56] 
A flow chart depicting the diagnosis of atypical CF starting with a sweat test. 
Individuals with intermediate sweat chloride test results are tested twice and then tested 
for genetic mutations in CFTR. If two CF causing mutations are identified, atypical CF 
can be diagnosed. If only one mutation is identified, a nasal potential difference test is 
performed. An abnormal result provides evidence for atypical CF diagnosis. If the nasal 
potential difference test is normal, CF is unlikely. [56] 
classified as ‘‘mild’’. Some patients with single organ involve-
ment resulting from CFTR dysfunction may be more appro-
priately given an alternative ‘‘diagnostic label’’ as recommended
in the World Health Organization (WHO) diagnostic list
(table 1).2 In these cases the importance of identifying a CFTR
mutation may be greater for the family (for genetic counselling
reasons) than for the index patient.
‘‘Classic’’ and ‘‘typical’’ CF are considered synonyms; the
same applies to ‘‘non-classic’’ and ‘‘atypical’’ CF. In the
current document the terms ‘‘classic’’ and ‘‘non-classic’’ will
Clinical suspicion
Sweat test
CF centre
Repeat sweat test
CFTR DNA test
Nasal PD
CFTR DNA test
Consult
genetic lab
Mutatation scanning
of CFTR gene
Inconclusive
Consider FU (at CF centre)
Consider
CF heterogeneity?
False + sweat test?
Consider alternative diagnosis
Appropriate investigations
and follow-up
Follow-up at CF centre
CF unlikely CFTR dysfunction
– non classic CF
– WHO diagnostic list
Classic CF
<30 mmol/l 30-60 mmol/l >60 mmol/l
<30 mmol/l 30-60 mmol/l >60 mmol/l
0 mutation
0 mutation 1-2 mutations
1 mutation 2 mutations
0 mutation 1 mutation 2 mutations
Clinical review
other diagnosis
Yes No
Normal Inconclusive Abnormal
Figure 1 Algorithm for the diagnosis of CF starting with the sweat test. When entering the algorithm it is advised to continue the diagnostic work up if
symptoms in a patient persist, as well as when symptoms have resolved but are highly suspicious for CF such as pancreatitis or Pseudomonas
aeruginosa lung disease. Wherever the algorithm ends with ‘‘CF unlikely’’ it is advised to inv stigate for alternative diagno es such as primary ciliary
dyskinesia, humoral immunodeficiency, Shwachman syndrome. For patients with CFTR dysfunction, the physician needs to decide the most appropriate
diagnostic label (non-classic CF or an item from the WHO diagnostic list shown in table 1 in patients with very limited symptoms). Patients with a
borderline sweat test (30–60 mmol/l), only one CFTR mutation identified, and an inconclusive nasal potential difference (PD) cannot at present be
classified correctly. They are at least CF carriers. In the presence of persistent symptoms they need structured follow up at an appropriate facility (for
some patients this may be the CF centre) and symptomatic treatment. Genetic counselling is important in these patients and their families. CFTR DNA
test: screening test to search for the most frequent mutations in the population from which the patient originates. Mutation scanning of CFTR gene: this
test is only necessary in som pat ents in whom the diagnosis cannot be supported by other means. The tests in the grey area are optional because two
clearly positive sweat tests are sufficient to support the diagnosis of CF in a compatible clinical setting. However, in most CF centres the CFTR DNA test
will be performed to confirm the diagnosis, to allow for further cascade screening if necessary, and at times for research purposes. Consult genetic lab:
in patients with an elevated sweat chloride level it would be unusual but not impossible not to find any mutation. In case of doubt about the diagnosis, a
mutation scanning of the complete gene can be done. A falsely positive sweat test and the possibility of CF heterogeneity also need to be considered.
628 De Boeck, Wilschanski, Castellani, et al
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A Case Study: Diagnosis of Atypical CF in a 55-year-old Female: 
In order to emphasize the difficulty that both a patient and physician go through in 
order to arrive at an atypical CF diagnosis, a case report of a 55-year old female is 
presented. The patient, denoted patient A, was interviewed, and medical records and 
radiographic film reports were obtained dating back to 2005. 
Patient A’s first sign of atypical cystic fibrosis was in 2005 at the age of 49. 
Patient A was involved in a car accident and transported to a trauma center by 
ambulance. A chest CT with contrast was performed. On the CT, minor reticular densities 
in the right middle lobe of the lung, representative of acute or chronic inflammatory 
disease were observed. Patient A was informed of the findings but suffered no respiratory 
symptoms, and did not follow up further. 
In 2007, patient A began allergy shots to control allergic symptoms to grasses and 
oak trees. She reports going through a turning point, where she became ill for a one- 
month period with a worsening cough. Patient A sought out her primary care physician 
who prescribed antibiotics. The exact antibiotic is unknown, as the chart from this 
physician was unable to be obtained. Although her initial fever subsided, patient A 
reported no change in the developing cough. Patient A followed up with her allergist who 
diagnosed her with adult onset asthma. 
In 2011, patient A’s cough was still worsening. Patient A sought out a local 
pulmonologist to attempt to control her cough. The pulmonologist ordered another chest 
CT with contrast. Findings of the chest CT included an increase in tiny centrilobular 
nodules in the middle and lower right lung, and a 5mm nodule in the upper lobe of the 
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left lung. Mild scarring and bronchiectasis was present in the right middle lobe. The 
pulmonologist obtained sputum samples and one sample came back positive for non-
tuberculosis mycobacterium avium complex (MAC), which is associated with atypical 
cystic fibrosis. The pulmonologist also ordered blood labs, and patient A was found to 
have a low neutrophil count, but was otherwise normal. Patient A was diagnosed with 
MAC and bronchiectasis without acute exacerbation and prescribed 500mg azithromycin 
to be taken 3 times per week, and a flutter valve to aid in clearing mucus. Patient A 
reports taking azithromycin for over one year. 
In 2012, patient A continued to have a persistent, chronic cough and was referred 
by her pulmonologist to an infectious disease specialist at a regional academic medical 
center. Patient A gave sputum samples, which were tested for the following: yeast or 
fungal elements, acid-fast bacillus, Staphylococcus aureus, and haemophilus 
parainfluenzae. Few Haemophilus parainfluenzae (beta lactamase negative) and staph 
aureus were found. All other tests were negative. Patient A was also tested for IgG 
subclasses 1-4 and IgE levels, all of which were within normal ranges. She was also 
tested for allergic bronchopulmonary aspergillosis (ABA), and was negative. After 
exhausting diagnostic tests, the infectious disease physician referred patient A to one last 
specialist the Chest Clinic at the same medical center. Patient A was given a sweat 
chloride test, which yielded an intermediate level result of 54mmol/L. Genetic testing 
was performed and patient A was found to be heterozygous for F508del and compound 
heterozygous for the 7T and 9T allele. A diagnosis of atypical cystic fibrosis was made. 
Patient A was prescribed a sodium chloride 7% inhalation solution to be used with a 
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nebulizer, an albuterol inhaler, and mometasone/formoterol (an inhaler with long acting 
beta 2 agonist and corticosteroid) to control her pulmonary symptoms and omeprazole for 
heartburn. Under proper management, a 2015 chest CT with contrast showed no new 
nodules in Patient A’s lungs. However, despite pharmacological intervention and a 
diagnosis, patient A still suffers from a debilitating chronic cough at all times of the day. 
Patient A’s diagnosis of atypical cystic fibrosis was missed by a general 
practitioner, an allergist, a pulmonologist and an infectious disease doctor. Patient A 
reports that her current specialists have told her that she likely would have never been 
diagnosed had she not come to a chest clinic at a regional medical center. In CF lung 
disease, the earlier the diagnosis, the better the outcome. Would patient A suffer from as 
debilitating a cough as she currently does with an earlier diagnosis and with proper 
disease management? Would multiple antibiotics have made a difference in her initial 
treatment of non-tuberculosis mycobacterium avium complex (NTM or MAC) bacteria? 
Evidence in the CF literature says yes to the first question, and is inconclusive on the 
second. Further, with the advent of new molecular therapies for CF treatment, patients 
with atypical CF are poised to benefit immensely. But, we cannot administer the drug if 
we cannot identify the disease first.  
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PART 4: TREATMENT OF ATYPICAL CF 
While the treatment regimen for classical cystic fibrosis is well defined, to date, 
no study focused entirely on the proper standard of care for a patient with atypical CF can 
be found via a PUBMED search. Luckily for patients diagnosed with atypical CF, most 
of the current CF management principles apply. However, patients with atypical CF are 
different from patients with the classical form of the disease and require an individualized 
treatment approach that depends on the severity of their symptoms and genotype [7]. 
Managing an atypical CF case in the same manner, as a classical CF case could possibly 
be too aggressive, however, a subset of patients with severe disease, diagnosed later in 
life may benefit from aggressive management.  
As with classical CF, lung infections and pulmonary exacerbations can be treated 
with a plethora of different antibiotics [58] depending on whether the infection is due to 
pseudomonas aeruginosa, non-tuberculosis mycobacterium avium complex (denoted as 
MAC or NTM), or another bacteria. Chest physical therapy, a flutter valve type 
instrument and inhaled hypertonic saline can be used to dislodge mucus in the airway 
[58, 77]. Pancreatic enzyme replacement therapies can be administered in a rare case of 
malabsorption in atypical CF. Lung transplant, although an option in classical CF, is 
generally not indicated for atypical CF lung disease. The survival rate two years after a 
lung transplantation is between 60 and 65% for all patients [78] – thus a lung transplant is 
likely too aggressive for nearly all patients suffering from atypical CF. A joint statement 
by the American Society for Transplant Physicians, American Thoracic Society, 
European Respiratory Society and Society for Heart and Lung Transplantation 
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recommended lung transplantation only in CF patients with a FEV1 of less than 30% of 
predicted or a rapid decline in lung function [98].  
While all of above therapies are helpful in treating the symptoms of the disease, 
they do not treat the underlying cause of the disease. Patients with atypical CF are, 
however, in an optimal position to reap the benefits of the research to create molecular 
therapies treating the underlying cause of the classical form of CF. To date, two drugs 
that target the molecular basis of CF have been approved for the FDA, and more are in 
the pipeline. Depending on a patients genotype, these drugs could already have a 
beneficial impact to a patient with atypical CF. In this section, the traditional therapies for 
classical CF that are applicable to atypical CF, and the new molecular therapies that 
could be used to treat the atypical form of the disease will be discussed. 
1) Traditional Therapies to Treat Pulmonary Atypical CF Symptoms: 
Traditional CF therapies that have an impact on lung function include antibiotics, 
bronchodilators, chest physical therapy, inhaled hypertonic saline, mucolytic agents, and 
orally administered non-steroidal anti-inflammatory drugs (NSAIDS). As recommended 
by the Cystic Fibrosis Foundation (CFF), the current order of administration of inhaled 
therapies is a bronchodilator; followed by inhaled hypertonic saline solution administered 
via nebulizer; followed by dornase alpha, followed by airway clearance, and then an 
aerosol based antibiotic [79]. A summary table created by the Cystic Fibrosis Foundation 
in 2013 of treatment options for pulmonary symptoms is included in Table 5 at the end of 
the section. 
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Antibiotics: 
Antibiotics are used to treat acute deteriorations in pulmonary exacerbations as 
well as bacterial infections in classical CF [58]. According to a Medscape review, the 
antibiotics (AB) used in CF patients to treat Pseudomonas aeruginosa include the 
following: inhaled tobramycin, or intravenous tobramycin with a penicillin based AB; 
inhaled aztreonam; gentamycin in combination with a penicillin based AB; piperacillin; 
cephalexin; ceftazidine; ciprofloxacin; trimethoprim, and chloramphenicol [80].  
A 2013 review by the Cystic Fibrosis Foundation (CFF) on current pulmonary 
treatments in CF recommends that patients suffering from mild lung disease and 
persistent pseudomonas aeruginosa infection should be prescribed daily inhaled 
aztreonam or tobramycin therapy in order to reduce pulmonary exacerbations, and 
improve quality of life [79]. Note that the CFF considers mild lung disease as a patient 
with 70-89% of predicted FEV1, moderate lung disease as a patient with 40-69% of 
predicted FEV1, and severe lung disease as a patient with less than 40% of predicted 
FEV1 [79]. For patients suffering from moderate to severe disease, inhaled aztreonam is 
the first line of therapy. In patients suffering from mild disease, one clinical study by 
Wainright found that thrice daily administration of inhaled aztreonam over 28 days in 
157 patients led to a 2.7% improvement in FEV1 over placebo and a modest 
improvement in quality of life [81].  
The CFF also recommended azithromycin for the treatment of persistent 
pseudomonas aeruginosa infection in airway cells based upon evidence found in four 
clinical trials finding that azithromycin decreased pulmonary exacerbations in patients 
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with CF. A Cochrane Review [82] supports this recommendation by the CFF, concluding 
that azithromycin is effective in decreasing pulmonary exacerbations, and increasing 
FEV1. Researchers with the CFF, did note that chronic usage of azithromycin may lead 
to non-tuberculosis mycobacterium infection (NTM), and recommended that patients be 
screened for NTM prior to beginning an azithromycin regimen [79]. The CFF also found 
that chronic administration of azithromycin should be considered in patients without 
pseudomonas aeruginosa infection to reduce pulmonary exacerbations [79]. 
To treat non-tuberculosis mycobacterial infection (NTM), the drug regimen of 
choice and length of time antibiotics are needed varies. One review by the American 
Thoracic Society recommended that non-tuberculosis mycobacterial disease in patients 
with nodular or bronchiectatic disease be given a three times per week regimen of 
clarithromycin, or azithromycin (a macrolide AB) for one year or until a non-tuberculosis 
mycobacterium avium complex culture is negative [83].  
Also of note, the CFF does not recommend the chronic usage of prophylactic anti-
staphylococcal antibiotics, and does not have sufficient evidence to recommend the 
chronic usage of other inhaled or oral antibiotics (as listed in the Medscape review) in 
patients with pseudomonas aeruginosa infection [79]. 
As to the question of whether a combination of antibiotics would be more 
beneficial, in a 2015 Cochrane Review [84], Hurley attempted to find evidence to support 
the use of multiple IV antibiotics in order to provide a more efficacious treatment for 
patients with CF suffering from pulmonary exacerbations. Hurley retrospectively 
analyzed 1717 CF patients, and found low quality evidence that patients who received 
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two IV antibiotics experienced a greater improvement in lung function than in patients 
who received only one IV antibiotic [84]. However, when he limited patient data to 
placebo controlled studies, no evidence was found to suggest that using two intravenous 
antibiotics is more effective in improving lung function than one intravenous antibiotic 
[84]. Further, there was no evidence showing that one route of administration (inhaled, 
intravenous, or oral) was better than another at treating pulmonary exacerbations [84]. 
Continuing research is needed to determine the most efficacious route of administration 
and antibiotic combinations. However, it should be noted that it is difficult to fully 
control a clinical trial due to ethics of giving a patient with CF a placebo over an 
antibiotic that is currently a front line therapy. 
Bronchodilators and Corticosteroids: 
Bronchodilators can be either short acting or long acting beta-2 agonists with or 
without an added corticosteroid [80]. Bronchodilators are administered via aerosol, 
nebulization, or a dry powder inhaler to CF patients [80]. In a 1999 study by Konstan 
published in Pediatric Pulmonology, it was found that 82% of sampled CF patients used 
inhaled bronchodilator therapy [85]. However, the data supporting the use is limited. 
According to Brand in a 2000 study published in the Journal of the Royal Society of 
Medicine, studies show that 50-60% of CF patients have an improved FEV1 after 
inhaling a bronchodilator, 30 percent show no change in FEV1, and 10-20% of patients 
have a lower FEV1 after use of an inhaled bronchodilator therapy [86]. Brand concluded 
that there is little evidence to support long-term usage of bronchodilators in patients with 
stable symptoms [86]. This raises the question of whether inhaled bronchodilator therapy 
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is efficacious in treating a patient with atypical CF, who is experiencing moderate, but 
stable symptoms. The CFF, in their 2013 review, concluded that there is insufficient 
evidence for or against the chronic use of beta-2 receptor agonists to decrease 
exacerbations and increase quality of life [79]. They note however, that short-term 
administration can benefit those with airway hyper responsiveness and prevent 
bronchospasm associated with the use of inhaled therapies [79]. The CFF also 
recommends against the chronic use of both inhaled and oral corticosteroids in patients 
without asthma or allergic bronchopulmonary aspergillosis [79]. However, approximately 
50% of CF patients have some form of asthma, and a bronchodilator and corticosteroid 
therapy will improve their symptoms [87]. It is also recommended that a bronchodilator 
be used prior to chest physical therapy or use of a flutter valve [80, 87]. 
 Chest Physical Therapy: 
Chest physical therapy involves percussion of the chest wall by a caretaker, and 
the patient coughing in order to move mucus into the larger airways in the lung. More 
recently, the flutter valve was introduced. A 1999 study by Gondor showed that patients 
using the flutter valve showed an increased forced vital capacity and FEV1 over chest 
physical therapy alone [88]. 
Hypertonic Saline: 
A 2012 review article by Reeves [77] published in the Scientific World Journal 
concluded that hypertonic saline solution is associated with an improvement in both lung 
function and pulmonary exacerbations, and that a synergistic effect is observed when 
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used combined with mucolytic agents such as dornase alfa (described in the following 
section). Three mechanisms of action have been proposed for inhaled hypertonic solution 
therapy. The first is that the salt solution draws water to apical membrane surface of the 
lung; the second is that LL-37, an antimicrobial peptide is released from 
glycosaminoglycans via a disruption in the electrostatic interaction between the two 
molecules; and third, is that the hypertonic saline solution disrupts the interaction 
between interleukin 8 (IL-8) and glycosaminoglycans allowing IL-8 to be degraded by 
proteolysis, thereby decreasing inflammation [77]. In their 2013 report, the CFF 
recommends the chronic usage of inhaled hypertonic saline to improve quality of life and 
decrease pulmonary exacerbations in all CF patients [79]. 
Mucolytic Agents: 
Mucolytic agents such as dornase alfa (pulmozyme) are used to reduce the 
viscosity and surface tension in the sputum of the lung [89]. Functioning as a 
recombinant human DNase, dornase alpha cleaves extracellular DNA in the sputum and 
improves the clearance of mucus secretions [80]. In their 2013 report, the CFF strongly 
recommends the use of dornase alpha in patients with moderate to severe disease and also 
recommends the use of dornase alpha in patients with mild disease [79]. The CFF found 
that patients with moderate to severe disease, and mild disease to have a substantial and 
moderate effect, respectively [79]. 
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Orally administered NSAIDS: 
A 2007 Cochrane Review [90] concluded that a high dose of ibuprofen could 
decrease the rate of progression of CF lung disease - especially in children. Subsequently, 
since the 2007 CFF pulmonary treatments review, ibuprofen has been recommended to 
prevent the loss of lung function in patients with an FEV1 value that is greater than 60% 
of predicted [79]. However, it is still unknown weather chronic use of ibuprofen will 
benefit adults, and more research is needed to reach a conclusion [79]. 
2) Traditional Therapies to Treat GI Based Atypical CF Symptoms: 
To treat pancreatic insufficiency or improve absorption during pancreatitis, 
pancrelipase, an enteric-coated pancreatic enzyme replacement therapy containing 
amylase, protease and lipase is administered [80]. Pancrelipase aids in protein, starch and 
fat digestion [80]. Since patients suffering from CF can suffer from fat-soluble vitamin 
deficiency, ADEK preparations containing vitamins A, D, E and K are supplemented due 
to malabsorption [80]. 
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Table 5: Pulmonary Treatments from the CFF. Adapted from [79] 
 
 
 
in QOL, as measured by CF Questionnaire–Revised, as well as
nutritional status. The authors observed a 48.1 mmol/L decrease
in sweat chloride concentration in treated patients compared
with placebo (P , 0.001), reflecting the impact of the drug on
the basic defect in CF. The incidence of adverse events was
similar in the two groups, with a lower proportion of serious
adverse events in those treated with ivacaftor compared with
placebo (24 vs. 42%).
Data published in abstract form after our systematic review
reported similar results in 52 children, aged 6–11 years, with at
least one G551D mutation treated with ivacaftor (150 mg twice
daily). After 24 weeks of treatment, FEV1 increased 12.6%
from baseline in the group receiving ivacaftor, compared with
0.04% in the placebo group (P , 0.0001) (27).
Overall, the committee rated the certainty of net benefit for
ivacaftor in patients with at least one G551D CFTR mutation as
high and the net benefit as substantial. In vitro data suggest that
there may be a role for ivacaftor in treating other mutations
where CFTR protein is present at the cell surface (23), but there
is insufficient information to make a recommendation for these
TABLE 3. SUMMARY OF RECOMMENDATIONS UNCHANGED FROM PREVIOUS GUIDELINES
Treatment Recommendation
Certainty of
Net Benefit
Estimate of
Net Benefit Recommendation
Inhaled tobramycin—moderate
to severe disease*
For individuals with CF, 6 years of age and older, with moderate to severe
lung disease and Pseudomonas aeruginosa persistently present in cultures
of the airways, the CF Foundation strongly recommends the chronic use
of inhaled tobramycin to improve lung function and quality of life, and
reduce exacerbations.
High Substantial A
Inhaled tobramycin—mild
disease*
For individuals with CF, 6 years of age and older, with mild lung disease
and P. aeruginosa persistently present in cultures of the airways, the CF
Foundation recommends the chronic use of inhaled tobramycin to
reduce exacerbations.
Moderate Moderate B
Dornase alfa—moderate to
severe disease*
For individuals with CF, 6 years of age and older, with moderate to severe
lung disease, the CF Foundation strongly recommends the chronic use of
dornase alfa to improve lung function, improve the quality of life, and
reduce exacerbations.
High Substantial A
Dornase alfa—mild disease* For individuals with CF, 6 years of age and older, with asymptomatic or mild
lung disease, the CF Foundation recommends the chronic use of dornase
alfa to improve lung function and reduce exacerbations.
High Moderate B
Inhaled hypertonic saline For individuals with CF, 6 years of age and older, the CF Foundation recommends
the chronic use of inhaled hypertonic saline to improve lung function and
quality of life and reduce exacerbations.
Moderate Moderate B
Azithromycin with
P. aeruginosa
For individuals with CF, 6 years of age and older, with P. aeruginosa persistently
present in cultures of the airways, the CF Foundation recommends the chronic
use of azithromycin to improve lung function and reduce exacerbations.
High Moderate B
Oral antistaphylococcal
antibiotics, prophylactic
use
For individuals with CF, the CF Foundation recommends against the prophylactic
use of oral antistaphylococcal antibiotics to improve lung function and quality
of life or reduce exacerbations.
Moderate Negative D
Inhaled corticosteroids For individuals with CF, 6 years of age and older, without asthma or allergic
bronchopulmonary aspergillosis, the CF Foundation recommends against the
routine use of inhaled corticosteroids to improve lung function or quality of life
and reduce pulmonary exacerbations.
High Zero D
Oral corticosteroids For individuals with CF, 6 years of age and older, without asthma or allergic
bronchopulmonary aspergillosis, the CF Foundation recommends against the
chronic use of oral corticosteroids to improve lung function, quality of life or
reduce exacerbations.
High Negative D
Other inhaled antibiotics For individuals with CF, 6 years of age and older, with P. aeruginosa persistently
present in cultures of the airways, the CF Foundation concludes that the
evidence is insufficient to recommend for or against the chronic use of other
inhaled antibiotics (i.e., carbenicillin, ceftazidime, colistin, gentamicin) to improve
lung function and quality of life or reduce exacerbations.
Low — I
Oral antipseudomonal
antibiotics
For individuals with CF, 6 years of age and older, with P. aeruginosa persistently
present in cultures of the airways, the CF Foundation concludes that the evidence
is insufficient to recommend for or against the routine use of chronic oral
antipseudomonal antibiotics to improve lung function and quality of life or reduce
exacerbations.
Low — I
Leukotriene modifiers For individuals with CF, 6 years of age and older, the CF Foundation concludes
that the evidence is insufficient to recommend for or against the routine chronic
use of leukotriene modifiers to improve lung function and quality of life or reduce
exacerbations.
Low — I
Inhaled or oral
N-acetylcysteine,
or inhaled glutathione
For individuals with CF, 6 years of age and older, the CF Foundation concludes that
the evidence is insufficient to recommend for or against the chronic use of inhaled
or oral N-acetylcysteine or inhaled glutathione to improve lung function and
quality of life or reduce exacerbations.
Low — I
Inhaled anticholinergics For individuals with CF, 6 years of age and older, the CF Foundation concludes that
the evidence is insufficient to recommend for or against the chronic use of inhaled
anticholinergic bronchodilators to improve lung function and quality of life or
reduce exacerbations.
Low — I
Definition of abbreviation: CF ¼ cystic fibrosis.
* Severity of lung disease is defined by FEV1% predicted as follows: normal, .90% predicted; mildly impaired, 70–89% predicted; moderately impaired, 40–69%
predicted; and severely impaired, ,40% predicted (1).
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Table 5: Continued- Taken from [79] 
 	   	  
mutations at this time. However, there is evidence that the use
of ivacaftor alone for individuals with two F508del CFTR muta-
tions, the most frequent genotype in CF, is not effective (28).
Aerosolized aztreonam for moderate to severe disease. P. aer-
uginosa is the most common pathogen in the airways of indi-
viduals with CF, and its acquisition is associated with more
rapid decline of lung function and decreased survival (29). We
identified three studies of inhaled aztreonam using doses rang-
ing from 75 to 225 mg administered two to three times in 515
individuals with FEV1 between 25 and 75% predicted (30–32).
Two trials found statistically significant absolute improvement
in FEV1 after aztreonam treatment for 28 days compared with
placebo (6.3–10.3%) (30, 32). A study that assessed lung func-
tion after 14 days of treatment found no difference between the
groups receiving aztreonam or placebo (31). McCoy and cow-
orkers (30) found that individuals receiving aztreonam twice
daily had a statistically prolonged time to an exacerbation
compared with placebo (92 vs. 71 d; P ¼ 0.002), but no such
difference was found for three-times-daily dosing (87 vs. 71 d;
P ¼ 0.182). Retsch-Bogart and coworkers (32) demonstrated
a decrease in hospital days for individuals treated with aztreo-
nam compared with placebo (0.5 vs. 1.5 d; P ¼ 0.049). QOL was
significantly improved in patients receiving aztreonam com-
pared with placebo (30, 32).
The trials of inhaled aztreonam were well designed and en-
rolled a large number of subjects. However, they were short term
with limited follow up. Long-term, placebo-controlled trials in
the current era are not possible, as inhaled antibiotics are stan-
dard of care for individuals with P. aeruginosa persistently pres-
ent in airway cultures. An 18-month open label study suggested
that long-term use of inhaled aztreonam every other month is
safe and effective (33), and not associated with increased resis-
tance to aztreonam (34). In addition, a study of 273 individuals
with CF aged 6 years or older demonstrated improved lung
function and fewer exacerbations over three 28-day cycles of
inhaled aztreonam compared with inhaled tobramycin (35).
Therefore, the committee recommends inhaled aztreonam for
chronic use with a high degree of certainty for a substantial net
benefit.
Aerosolized aztreonam for mild disease. There is one study of
inhaled aztreonam in patients with FEV1 greater than 75% pre-
dicted. Wainwright and coworkers (36) studied the effect of
28 days of aztreonam (75 mg thrice daily) on 157 patients, 6 years of
age or older, with mild lung disease and P. aeruginosa infection.
Aztreonam led to a 2.7% relative improvement in FEV1 com-
pared with placebo (P ¼ 0.021) and a modest improvement in
QOL. Given this one well designed study with a large number
of subjects, the committee rated both the certainty and magni-
tude of net benefit as moderate.
KEY UNANSWERED QUESTIONS
Many of the issues highlighted in the 2007 version of these guide-
lines remain unresolved today, including: prioritization of ther-
apies; interactions between medications; effect of bacterial
resistance; optimal use of medications in children under 6 years
of age; and unintended consequences of long-term medication
use. There remain few data to determine the sequence in which
medications should be administered for optimal effectiveness.
The CF Foundation has recommended the following order of in-
haled medications: bronchodilator; hypertonic saline; dornase
alfa; airway clearance; and aerosolized antibiotic. We agree that
this is a rational approach; however, further study is warranted to
assure that it is the optimal approach.
Recommendations for chronic use of medications are based
on relatively short trials. The committee recognizes that many
TABLE 4. NEW AND MODIFIED RECOMMENDATIONS
Treatment Recommendation
Certainty of
Net Benefit
Estimate of
Net Benefit Recommendation
Ivacaftor* For individuals with CF, 6 years of age and older, with at least one G551D CFTR mutation,
the Pulmonary Clinical Practice Guidelines Committee strongly recommends the chronic
use of ivacaftor to improve lung function and quality of life and reduce exacerbations.
High Substantial A
Inhaled
aztreonam—moderate
to severe disease†
For individuals with CF, 6 years of age and older, with moderate to severe lung disease and
Pseudomonas aeruginosa persistently present in cultures of the airways, the CF Foundation
strongly recommends the chronic use of inhaled aztreonam to improve lung function
and quality of life.
High Substantial A
Inhaled aztreonam—mild
disease†
For individuals with CF, 6 years of age and older, with mild lung disease and P. aeruginosa
persistently present in cultures of the airways, the CF Foundation recommends the
chronic use of inhaled aztreonam to improve lung function and quality of life.
Moderate Moderate B
Chronic use of ibuprofen
(age , 18 yr)
For individuals with CF, between 6 and 17 years of age, with an FEV1 > 60% predicted,
the CF Foundation recommends the chronic use of oral ibuprofen, at a peak plasma
concentration of 50–100 mg/ml, to slow the loss of lung function.
Moderate Moderate B
Chronic use of ibuprofen
(age > 18 yr)
For individuals with CF, 18 years of age and older, the CF Foundation concludes that
the evidence is insufficient to recommend for or against the chronic use of oral ibuprofen
to slow the loss of lung function or reduce exacerbations.
Low — I
Azithromycin without
P. aeruginosa
For individuals with CF, 6 years of age and older, without P. aeruginosa persistently present
in cultures of the airways, the CF Foundation recommends the chronic use of
azithromycin should be considered to reduce exacerbations.
Moderate Small C
Chronic inhaled
b2-adrenergic
receptor agonists
For individuals with CF, 6 years of age and older, the CF Foundation concludes that the
evidence is insufficient to recommend for or against chronic use of inhaled b2-adrenergic
receptor agonists to improve lung function and quality of life or reduce exacerbations.
Low — I
Oral antistaphylococcal
antibiotics, chronic use
For individuals with CF, 6 years of age and older, with Staphylococcus aureus persistently
present in cultures of the airways, the CF Foundation concludes that the evidence is
insufficient to recommend for or against the chronic use of oral antistaphylococcal
antibiotics to improve lung function and quality of life or reduce exacerbations.
Low — I
For definition of abbreviation, see Table 3.
* CF Foundation personnel did not participate in any activity related to ivacaftor.
y Severity of lung disease is defined by FEV1% predicted as follows: normal, .90% predicted; mildly impaired, 70–89% predicted; moderately impaired, 40–69%
predicted; and severely impaired, ,40% predicted (1).
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3) Current and Future Targeted Therapies: 
Since the discovery that cystic fibrosis was the result of a genetic mutation in the 
CFTR gene in 1989, the race has been on to develop small molecule based therapies that 
target the underlying cause of the disease. Because there are six general classes of 
mutations with varying effects on the total amount of functional CFTR channel translated 
or present at the apical surface in CF, drugs that treat the disease must be specific to the 
mutation. In general, a drug must be either a CFTR potentiator, or a corrector. A drug that 
is a CFTR potentiator increases ion flow through the CFTR channel that is already 
present at the apical membrane, and a CFTR corrector is a compound that increases the 
delivery of CFTR protein to the apical membrane [17].  
The first approved drug that treats the underlying cause of CF at the molecular 
level is Ivacaftor, a CFTR potentiator for patients with at least one copy of the G551D 
mutation [91]. The G551D mutation is a class III CFTR mutation, of which 5% of CF 
patients carry. In patients with the G551D mutation, CFTR protein is processed and 
delivered to the apical membrane, but there is a block in channel gating, and the channel 
does not permit chloride ion to flow through [58].  
Clinical studies of ivacaftor showed the following: In a 2013 double blinded, 
randomized, placebo control trial by Davies, Ivacaftor was found to increase FEV1 by 
12.5 percentage points, and significantly decrease sweat chloride levels to the 
intermediate range [91]. Mckone, also in 2013, showed that ivacaftor decreases the rate 
of decline in FEV1, and that ivacaftor was generally well tolerated, with only 1% of 
children and adults taking the drug having discontinued the trial due to adverse events 
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[92]. Mckone also showed that over 144 weeks of taking ivacaftor, children and adults 
gained an average of 4.1kg and 14.8kg respectively [92]. Rowe, demonstrated that 
ivacaftor caused a significant decline in pseudomonas aeruginosa infection, decreased 
sweat chloride to an average of 53.8mmol/L, improved BMI, and increased the rate of 
weight gain compared to placebo [93]. Another study showed that ivacaftor improved 
FEV1 in patients with a R117H mutation [17]. Thus, if a patient presenting with atypical 
CF has a single copy of the G551D mutation, or a single copy of the R117H mutation, 
ivacaftor is likely to improve their clinical outlook. 
Overall, clinical studies showed that ivacaftor was a breakthrough for patients 
with a G551D mutation. It also gave researchers a proof of concept: restoring CFTR 
channel function causes a large improvement in symptoms for individuals with the 
G551D mutation, independent of genetic modifiers or environmental factors that are 
known to influence disease severity. However, this breakthrough left more than 90% of 
CF patients without any new hope. According to Boyle’s 2014 CFF presentation, 87% of 
patients have 1 copy of the F508del, of which 46.5% are homozygous, and 39% are 
heterozygous [17]. For them, ivacaftor was not expected to have an effect. Flume, in a 
trial published in an article in Chest, confirmed that ivacaftor has no effect on patients 
who are homozygous for the F508del mutation [94]. The F508 mutation is a class II 
mutation resulting in aberrant processing of the protein. For these patients, a CFTR 
corrector would be needed, which was in the pipeline. The compound was lumacaftor. 
Lumacaftor is a drug that was shown to correct F508del misprocessing and increase the 
amount of CFTR protein that is located at the apical cell surface [95]. 
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The combination of lumacaftor and ivacaftor (Orkambi) was approved by the 
FDA in July 2015 for patients who are homozygous for the F508del mutation and older 
than twelve years old. Wainright showed in two phase III, randomized, double blind, 
placebo controlled trials for Orkambi that FEV1 improved 4.3 to 6.7%, pulmonary 
exacerbations declined 30-39%, and that there was a lower rate of hospitalization for 
patients in the study [95]. This was another breakthrough, the difference being that this 
time the majority of patients suffering from CF served to benefit. However, Orkambi 
does not reduce sweat chloride or improve FEV1 in patients who are heterozygotes for 
the F508del mutation. Thus, this drug is likely to have no impact on patients with atypical 
CF [80]. Despite the clinical success of Orkambi, there is a controversy over the cost of 
the medication, which retails for almost $260,000 per year - although Orkambi is cheaper 
than ivacaftor, which costs $310,000 per year [96]. It is likely that these drugs will strain 
the Medicare, Medicaid, and private health insurance system in the United States, causing 
a net increase in health care costs to the system, and that some patients may not be able to 
get the drug due to the exorbitant cost. Government or private insurance control over who 
gets these targeted medications may be a limiting factor in CF patient survival in the 
future. 
However, for atypical CF patients, another compound, VX-661, which works like 
lumacaftor is in the pipeline. A phase II randomized, double blind, placebo controlled 
study of VX-661 in combination with ivacaftor in 2012 showed a 9% increase in FEV1 
over ivacaftor alone [97]. VX-661 is still under investigation, so for now, F508del 
heterozygotes, of which many patients with atypical CF are, will have to wait. The cost of 
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the VX-661 is likely to be near the cost of Orkambi, and whether or not an atypical CF 
patient’s insurer will cover the drug will be a determinant in the clinical outcome for 
atypical CF patients. 
Other therapies in the pipeline involve gene therapy and anti-inflammatory drug 
development. Shire Pharmaceuticals is working on an aerosol based therapy containing 
normal CFTR mRNA designed to deliver wild type mRNA to the lung, where it could be 
translated into proper folded protein [98]. Also, sildenafil, a phosphodiesterase inhibitor 
is being tested for anti-inflammatory properties in patients with CF [98].  
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PART 5: CONCLUSIONS 
Atypical cystic fibrosis, also referred to in the literature as non-classical CF, adult 
onset CF, adult diagnosed CF, or CFTR related disease is a less severe form of CF in 
which patients have mild mutations in the CFTR gene. Mutations often involve one 
severe class I, II, or III mutation on one chromosome in combination with a mild class IV 
or V mutation on the second chromosome, allowing for residual function of the CFTR 
channel, and preventing the classical presentation of cystic fibrosis from occurring. 
Perhaps, as some have already suggested, the best name for atypical CF is residual 
function CF, as this characterizes the underlying problem of the disease most precisely. 
Acute respiratory symptoms are the most prominent symptoms at the time of diagnosis, 
although sinus disease, idiopathic pancreatitis, a familial history of CF and male 
infertility are also signs. Diagnosis of atypical CF is difficult and expensive, requiring 
specialty physicians and genetic testing. Increasing physician awareness of the adult 
population with CF is a paramount in improving the diagnosis, care and treatment of 
patients with atypical CF. Now that newborn screening for CF occurs in all 50 states of 
the Unites States, the diagnosis of atypical CF may be rare after the next 20 years. 
However, we are still learning about new, mild mutations, and it is difficult and 
expensive to test a newborn for every possible mutation. Therefore, some people may not 
be diagnosed until adulthood despite newborn screening. Diagnosis of atypical CF is 
important, as pulmonary symptoms can still be severe. Patients with atypical CF likely 
stand to benefit the most from the recent advances in molecular therapy for classical CF, 
but we cannot treat a patient with these new drugs without a diagnosis. A small increase 
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in functional CFTR in patients with atypical CF, who already have CFTR with residual 
function, should have a profound clinical impact. However, until a compound that is 
effective for patients heterozygous for the F508 mutation is approved for use, many 
patients with atypical CF are still relegated to the use traditional therapies that treat the 
symptoms of the disease, rather than the underlying cause. Once a drug is approved, a 
cost benefit analysis will have to be performed by patients, physicians, and the health 
care system, as the cost of the drug will likely be over $200,000 per year if Ivacaftor and 
Orkambi are any indication. Further research, perhaps a prospective study following adult 
males diagnosed with CBAVD and two CFTR mutations would provide insight into the 
temporal relationship between CFTR mutations and the development of symptoms of 
atypical CF. One study mentioned earlier also noted that a higher proportion of females 
than males diagnosed with CF as an adult. Further research should be aimed at 
determining if atypical CF is more prominent in either sex. A comprehensive document 
providing information on the management of atypical CF has yet to be made.. Studies 
evaluating the efficacy of treatment in mild disease are few and far between, making it 
difficult for physicians to come to a conclusion on the best course of treatment for 
atypical, or mild CF cases. Further, once a molecular therapy for treating F508del 
heterozygotes exists, research will need to determine how much residual damage has 
been accrued in the lung in patients with atypical CF, and what therapies will need to be 
included in a therapeutic regimen in addition to molecular based therapy in order to 
provide the largest benefit to the patient. 
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